Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trial

Clinical Cancer Research

Volumn 10, Issue 14, 2004, Pages 4639-4644

  Zhu, Li ^a   Chow, Louis W C ^a,c   Loo, Wings T Y ^a   Guan, Xin Yuan ^a   Toi, Mazakazu ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CELECOXIB; EXEMESTANE; LETROZOLE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CYCLOOXYGENASE INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; PROGNOSIS; PYRAZOLES; RECEPTOR, ERBB-2; SULFONAMIDES; TREATMENT OUTCOME; TRIAZOLES;

EID: 3242712110     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0057     Document Type: Article

References (43)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGurie WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC) 1987;235:177-82.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC) 1989;244:707-12.
3. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
4. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808.
5. Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518-25.
6. Berns EM, Foekens JA, van Staveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene (Amst.) 1995;159:11-8.
7. Archer SG, Eliopoulos A, Spandidos D, et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995;72:1259-66.
8. Carlomagno C, Perrone F, Gallo C, et al. c-Erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702-8.
9. Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003;21:1967-72.
10. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and /or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J Clin Oncol 2001;19:3808-16.
11. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blinded multicenter study. Ann Oncol 2001;12:1527-32.
12. Dixon JM, Jackson J, Renshaw L, Miller WR. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 2003;86(3-5):295-9.
13. Perloff M, Lesnick GJ. Chemotherapy before and after mastectomy in stage III breast cancer. Arch Surg 1982;117:879-81.
14. Schick P, Goodstein J, Moor J, Butler J, Senter KL. Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol 1983;22:278-82.
15. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst (Bethesda) 1990;82:1539-45.
16. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93.
17. Horobin JM, Preece PM, Dewar JA, Wood RAB, Cushieri A. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 1991;78:213-7.
18. Dixon JM, Love CD, Bellamy CO, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001;66:191-9.
19. Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR. The effect of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blinded, single-center study. Clin Cancer Res 2000;6:2229-35.
20. Dixon JM, Anderson T, Miller WR. Phase II b study of neoadjuvant exemestane (EXE) in locally advanced breast cancer. Proc Am Soc Clin Oncol 2001;20:1908.
21. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
22. Chow LW, Wong JL, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol 2003;86(3-5):443-7.
23. Wright C, Nicholson S, Angus B, et al. Relationship between cerbB2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65:118-21.
24. Newby JC, Johnston SRD, Smith IE, Dowsett M. Expression of epidermal growth factor receptor and cerbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997;3:1643-51.
25. Bianco AR, DeLaurentis M, Carlomagno C. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between cerbB2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 1998;17:97.
26. Muss HB, Berry DA, Thor AD, et al. Lack of interaction of tamoxifen use and ErbB-2/ HER-2/ neu expression in CALGB 8541: a randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin, and fluorouracil (CAF) in node-positive primary breast cancer. Proc Am Soc Clin Oncol 1999;18:68.
27. Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998;4:7-12.
28. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003;16:173-82.
29. Wang S, Saboorian MH, Frenkel E, Hyman L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 2000;53:374-81.
30. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 2000;13:866-73.
31. Lebeau A, Deimling D, Kaltz C, et al. HER/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354-63.
32. Hoang MP, Sahin AA, Ordòñez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast cancer. Am J Clin Pathol 2000;113:852-9.
33. Jiminez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
34. Birner P, Oberhuber G, Stani J, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001;7:1669-75.
35. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-7.
36. Onody P, Bertrand F, Muzeau F, Bieche I, Lidereau R. Fluorescence in situ hybridisation and immunohistochemical assays for HER-2/neu status determination. Arch Pathol Lab Med 2001;125:746-50.
37. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-21.
38. De Potter CR, Schelfhout AM. The neu-protein and breast cancer. Virchows Arch 1995;426:107-15.
39. Yu DH, Liu BL, Tan M, et al. Overexpression of cerbB2/neu in breast cancer cells confers increased resistance to Taxol via MDR-1-independent mechanisms. Oncogene 1996;13:1359-65.
40. Dixon JM, Love CD, Renshaw L, et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer 1999;6:227-30.
41. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993;24:85-95.
42. Kurokawa H, Lenferink AE, Simpson JF, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887-94.
43. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003:63:6523-31.